Tagged with BI

Pharma Legal Handbook The key facts about Regulatory Reforms in Saudi Arabia. Prepared in association with STA, an international law firm, this is an extract from The Pharma Legal Handbook: Saudi Arabia, available to purchase here for GBP 99.   1. Are there proposals for reform or significant change to the healthcare system?…

Pharma Legal Handbook Cannabinoid drugs, medicinal cannabis and opioid drugs in Saudi Arabia – a comprehensive legal overview.. Prepared in association with STA, an international law firm, this is an extract from The Pharma Legal Handbook: Saudi Arabia, available to purchase here for GBP 99.   Cannabinoid Drugs 1. Are Cannabinoid Drugs authorized…

Spain CataloniaBio & HealthTech is an industry association representing the biomedicine and health sector in Catalonia. Its CEO, Judit Anido, explains how the region’s entrepreneurial spirit is helping it lead Spain in research and innovation, and comments on regulatory changes needed to help small- and medium-sized companies grow into a competitive…

Spain Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19 treatment, and the reimbursement challenges faced by rare disease players in Spain. Moreover, De Mora highlights Sobi’s vast clinical trials…

Italy   In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s third largest in Europe and sixth largest globally. Giese also touches on ensuring the affiliate’s product launch readiness, consistently increasing…

Global Recent reportage from Global Data Research and Clinical Trials Arena has ranked the world’s leading biopharma companies best positioned to take advantage of future biosimilars disruption. The ranking considers the number of jobs listed by each company mentioning biosimilars, deals conducted, and company filing mentions in the period between January…

Spain The Spanish Society of Biotechnology (SEBiot) is a non-profit organization established by academics and researchers to promote the sector through knowledge exchange and is a Branch Office of the European Federation of Biotechnology (EFB). Its current president, Fernando Peláez, explains the main activities of this scientific society, how SEBiot is…

Europe At the recent FT webinar, ‘Supporting Pharma Innovation in Europe’, high-level representatives from Roche, Bayer, and the European Commission weighed in on how European pharma’s competitive position on innovation is being challenged and the policy measures that need to be enacted to solve this issue. Read on for five key…

Spain While Spain’s scientific infrastructure has long been hailed as world-class, the southern European nation has often struggled to translate its excellent science into viable commercial companies. However, a growing cadre of clinical-stage firms are aiming to change that narrative and become the biotech success story that Spain so desperately craves.…

Saudi Arabia Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across pharma distribution through SITCO Pharma, manufacturing (both for its own products and as a contract manufacturing organisation (CMO)) via AJA…

MEA Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma executives overseeing his region need to succeed.   As region head for a company that is only 40 years old,…

Saudi Arabia While Saudi Arabia is becoming an increasingly attractive investment destination for global pharma, some stakeholders continue to have concerns about whether the country’s intellectual property (IP) protection system is truly fit for purpose.   Oscar Delgado of BMS is one such stakeholder. “An adequate IP system, including regulatory data protection…